Laurus Labs (LAURUSLABS) Q3 25/26 earnings summary

Executive summary

• Achieved strong operational and financial performance in Q3 and 9M FY2026, with consolidated revenue for Q3 at ₹1,778.29 crore and 9M revenue at ₹5,044.48 crore, driven by growth in generics and CDMO segments.

• Net profit after tax for Q3 was ₹251.88 crore, with 9M net profit at ₹610 crore, up 388% year-over-year.

• Continued investments in peptide, ADC, and gene therapy infrastructure, and expanded leadership in ARV segment.

• Significant CAPEX investment, representing 15% of sales, to expand manufacturing and niche capabilities.

• Key investments made in Laurus Bio and KRKA Pharma joint ventures during the quarter.

Financial highlights

• Q3 FY2026 revenue: ₹1,778 crore, up 26% year-over-year; 9M FY26 revenue: ₹5,001 crore, up 30% year-over-year.

• Gross margin for Q3: 60.9%; nine-month gross margin: 60.1%, up 4.3 percentage points.

• Q3 EBITDA: ₹485 crore (27% margin); 9M EBITDA: ₹1,303 crore (26.1% margin), up 104% year-over-year.

• Net profit for 9M: ₹610 crore, up 388% year-over-year; Q3 PAT: ₹252 crore, up 174% year-over-year.

• Net debt-to-EBITDA improved to 1.2x; ROCE at 18.5%.

Outlook and guidance

• Confident in delivering healthy operational growth for FY2026, supported by robust CDMO outlook and stable ARV business.

• Gross margins expected to remain around 60% for the coming quarter and next financial year.

• CapEx for FY2026 and FY2027 projected at over ₹1,000 crore each year.

• The company is evaluating the impact of new Indian labour codes effective November 2025.